|Bid||0.00 x 800|
|Ask||0.00 x 1800|
|Day's Range||2.30 - 2.45|
|52 Week Range||1.29 - 4.84|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.84|
Correvio Pharma Corp, Formerly Cardiome Pharma Corp, Announces Stock Ticker Symbol Change to CORV
VANCOUVER , May 17, 2018 /CNW/ - Correvio Pharma Corp. (NASDAQ: CRME / TSX: COM), formerly Cardiome Pharma Corp., today announced that its partner Eddingpharm has enrolled the first patient in a randomized, double-blind, placebo-controlled, Phase 3 clinical study evaluating Brinavess® versus placebo in patients with recent onset atrial fibrillation (AF). Approximately 240 patients are expected to be enrolled at an estimated 30 clinical trial sites in China . The primary objective of the study is to demonstrate the effectiveness of Brinavess in the conversion of recent onset AF to sinus rhythm, compared to placebo. Secondary objectives include assessment of the safety and tolerability of Brinavess, time to conversion of AF to sinus rhythm and pharmacokinetics, among others.
The Vancouver, British Columbia-based company said it had a loss of 24 cents per share. The cardiovascular drug maker posted revenue of $6.5 million in the period. In the final minutes of trading on Tuesday, ...
VANCOUVER , May 15, 2018 /CNW/ - Correvio Pharma Corp. ("Correvio"), formerly Cardiome Pharma Corp. ("Cardiome") (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has completed its previously announced strategic transaction with Cipher Pharmaceuticals Inc. ("Cipher") (CPH.TO) whereby Cipher has acquired Correvio's Canadian business portfolio, including the Canadian rights to Brinavess®, Aggrastat®, Xydalba™ and Trevyent®, effective today. Cardiome has undergone a corporate restructuring by way of a statutory plan of arrangement (the "Arrangement"). Pursuant to the Arrangement, all of the outstanding common shares of Cardiome have been assigned and transferred to Cardiome's newly created wholly-owned subsidiary, Correvio Pharma Corp., in exchange for common shares of Correvio. Each former shareholder of Cardiome now holds the same pro rata interest in Correvio as it held in Cardiome immediately prior to completion of the Arrangement. Correvio has acquired and will hold all of Cardiome's pre-transaction assets, other than the Canadian business portfolio acquired by Cipher under the Arrangement. Cipher has acquired all of the outstanding common shares of Cardiome, which holds only the transferred Canadian business.
Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call
Measuring Cardiome Pharma Corp’s (TSX:COM) track record of past performance is a useful exercise for investors. It enables us to understand whether or not the company has met or exceedRead More...
Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess®
Cardiome Pharma Corp. (CRME) issued a press release reporting 2017 full-year results on March 13, 2018, and filed its 2017 financial statements and management discussion & analysis on SEDAR three weeks later. During 2017, Cardiome advanced Xydalba in Europe with a commercial launch in several EU states.
NASDAQ:CRME TSX:COM VANCOUVER , March 28, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) announces that Dr. William Hunter , President and CEO and Justin Renz , Chief Financial Officer, ...
NEW YORK, NY / ACCESSWIRE / March 22, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...
VANCOUVER, March 22, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, announced today that Health Canada has accepted its New Drug Submission (NDS) for review of Xydalba™ (dalbavancin hydrochloride) and granted Priority Review status to the application. Cardiome expects to receive an approval decision for Xydalba during the third quarter of 2018. Under the proposed strategic transaction between Cardiome and Cipher Pharmaceuticals Inc. announced earlier this week, upon the close of the transaction, Cipher would sublicense the commercial rights to Xydalba as part of the Canadian business portfolio proposed for acquisition. "Health Canada's acknowledgement regarding the completeness of the NDS submission for Xydalba and granting of Priority Review are important milestones for Cardiome," said Kiran Bhirangi, M.D., Vice President, Clinical Development and Medical Affairs.
Stock Monitor: Apricus Biosciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 22, 2018 / Active-Investors.com has just released a free research report on Cardiome Pharma Corp. (NASDAQ: CRME ...
CARDIOME PHARMA CORP (NASDAQ: CRME ) announced Tuesday it has agreed to divest its Canadian business to Cipher Pharmaceuticals for the U.S. dollar equivalent of $19.7 million. The Analyst Canaccord Genuity's ...
Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome
MISSISSAUGA, ON, and VANCOUVER, March 20, 2018 /PRNewswire/ - Cipher Pharmaceuticals Inc. (CPH.TO) and Cardiome Pharma Corp. (Nasdaq:CRME and TSX:COM), today announced their entry into a definitive arrangement agreement pursuant to which Cipher will acquire the Canadian business portfolio of Cardiome. The proposed transaction will be completed pursuant to the acquisition by Cipher of all of the outstanding shares of Cardiome, following a restructuring of Cardiome pursuant to a statutory plan of arrangement under the Canada Business Corporations Act. Pursuant to the arrangement, Cardiome shareholders will receive common shares, on a one-for-one ratio, of a newly created Canadian entity named Correvio Pharma Corp. that will apply for a substitution listing on the Nasdaq and TSX. Correvio will acquire and hold all of Cardiome's pre-transaction assets, excluding the Canadian business portfolio being acquired by Cipher under the arrangement. The arrangement is described in further detail below.
Cardiome was involved in substantial activity during the prior twelve months, beginning with the recognition of sales for Zevtera/Mabelio, the launch of Xydalba in several new geographies, and the expansion of the reach of Brinavess. China’s regulatory authority granted Aggrastat an additional indication and SteadyMed is on track for its new drug application (NDA) for Trevyent. As we began 2018, Esmocard posted record months in both January and February. In September, Cardiome entered into an agreement with Basilea to commercialize ceftobiprole (Zevtera/Mabelio) in 34 European countries and Israel. Following the transaction, revenues were recognized on Cardiome’s income statement and beginning January 1st, 2018 all of Basilea’s sales representatives were added to Cardiome’s sales force. Management commentary noted that they were able to achieve historical peak sales levels of the drug in January and surpass that in February, suggesting that better days are still ahead.
The Vancouver, British Columbia-based company said it had a loss of 24 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...